Mediastinal lesion
Conditions
Interventions
Observation group:None
Sponsors
The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years. 2.Willing to participate and has provided written informed consent. 3.Scheduled to undergo flexible bronchoscopy for one or more of the following indications: Suspected tracheal, bronchial, or pulmonary neoplasm or tumor-like lesion requiring histopathologic classification, assessment of extent, and staging. Unexplained hemoptysis persisting for = 1 week. Lower respiratory tract infection that remains undiagnosed, progresses rapidly, responds poorly to antimicrobials, or shows persistent or slow-resolving lesions, especially in patients with immune compromise. New pulmonary infiltrates after solid-organ or bone-marrow transplantation, or suspected graft-versus-host disease or lung allograft rejection. Unexplained cough with atypical progression or poor response to therapy, raising suspicion of tracheobronchial tumor, foreign body, or other pathology. Sudden-onset wheeze or stridor of unknown origin, particularly localized rhonchi or wheezes, necessitating exclusion of large-airway stenosis or obstruction. Unexplained diffuse parenchymal lung disease such as interstitial pneumonia, sarcoidosis, pulmonary alveolar proteinosis, or occupational lung disease. Unilateral whole-lung, lobar, or segmental atelectasis of any etiology. Suspected airway trauma following thoracic trauma. Clinical and radiologic suspicion of tracheobronchial fistulae (e.g., tracheoesophageal or bronchopleural fistula). Suspected airway foreign body. Unexplained mediastinal lymphadenopathy or mediastinal mass.
Exclusion criteria
Exclusion criteria: 1. Severe cardiopulmonary comorbidity, including but not limited to: Cardiac disease classified as New York Heart Association (NYHA) functional class III or IV. Severe pulmonary hypertension or cor pulmonale. Acute exacerbation of severe chronic obstructive pulmonary disease (COPD). Severe pulmonary fibrosis or diffuse alveolar hemorrhage. 2.Any contraindication to bronchoscopy—e.g., clinically significant coagulopathy, massive hemoptysis, or intolerance of anesthesia. 3.Psychiatric illness, severe neurosis, or any other condition precluding valid informed consent. 4.Use within the past 4 weeks of omalizumab, nitric-oxide synthase inhibitors, leukotriene-receptor antagonists, or systemic corticosteroids. 5. Allergic disease within the past 4 weeks or current use of antihistamines or other anti-allergic medications. 6.Respiratory procedures within the preceding hour—e.g., spirometry, bronchial challenge tests, or nebulized therapy. 7.Smoking within the preceding hour. 8.Vigorous physical exercise within the preceding hour. 9. Food intake within the preceding 3 hours. 10.Consumption on the day of testing of alcohol, strong tea, coffee, or other stimulant beverages. 11. Inability to cooperate with FeNO measurement. 12. Participation in another clinical trial within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FeNO; | — |
Countries
China
Contacts
Public ContactYe Fan
The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital)
Outcome results
None listed